• / Free eNewsletters & Magazine
  • / My Account
Home>Funds>PIMCO Municipal Income II

PIMCO Municipal Income II

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Genentech’s Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to Rituxan

    Genentech’s Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to Rituxan

  2. Seattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Diffuse Large B-cell Lymphoma at ASH Annual Meeting

    Seattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Diffuse Large B-cell Lymphoma at ASH Annual Meeting

  3. Year in Review: Municipal CEFs

    We take a look at 2012's municipal CEF performance, distribution cuts, mergers, and more.

  4. A Closer Look at CEF Duration Risk

    An examination of 10 CEFs with the highest duration risk.

  5. Teva Secures European Approval of Trisenox® for First Line Treatment of Low to Intermediate Risk Acute Promyelocytic Leukemia (APL)

    Teva Secures European Approval of Trisenox® for First Line Treatment of Low to Intermediate Risk Acute Promyelocytic Leukemia (APL)

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.